

Data Collection Protocol

	Screen	Treatment - 24 weeks									Follow-Up		
	30 days	0 (BL)	2	4	6*	8	12	16*	20	24	4	12	
SE: Screening Evaluation	CC												
SC: Screening Criteria	CC												
RF: Randomization Form		PH											
SD: Screening Demographic	PT												
AD: Adherence Self-Efficacy Scale		PT		PT			PT			PT	PT		
QL: Quality of Life		PT		PT			PT			PT	PT		
QD: Chronic Liver Disease		PT		PT			PT			PT	PT		
CD: CES-D		PT		PT			PT			PT	PT		
PD: Patient Diary Summary		CC	CC	CC			CC	CC		CC	CC		
LE: Laboratory Evaluation	CC	CC	CC	CC			CC	CC		CC	CC	CC	
VE: Visit Evaluation			CC	CC			CC	CC		CC	CC	CC	
ML: Concomitant Medications		AS NEEDED											
AE: Adverse Event		AS NEEDED											
DC: Dose Change			AS NEEDED										
DS: Discontinuation of Treatment or Study		AS NEEDED											

Pharmacokinetics (ml)	Schedule 1	Blood		9					9			9-12		
		Urine		10					10			10		
	Schedule 2	Blood			9			9			9			
		Urine			10			10			10			
	Non PK pts	Blood		3	3	3		3	3		3	3		
		Urine		10	10	10		10	10		10	10		

Whole blood for genetics component (ml)***		20												
Serum (ml) **		10						5			5	5		
Plasma (ml)		5						3			3	3		

* Phone Interview

** Includes HCV RNA sample for central testing laboratory (treatment weeks 0, 12, 24, and follow-up week 4)

*** The sample for the genetic component should be collected at the baseline visit or at any of the subsequent protocol visits throughout the course of the study.

PT	Patient
CC	Clinical Coordinator
GC	GCRC personnel
PH	Pharmacist